Health Care/Hospital

Alma, a Sisram Medical Company, Advances the Future of Intelligent Aesthetics at IMCAS World Congress 2026

New clinical evidence highlights a smarter, technology-driven approach to scar management, rejuvenation, and tattoo removal HONG KONG, Feb. 6, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a g...

2026-02-06 16:30 4311

PharmaResearch Receives U.S. FDA Clearance to Initiate Phase 1 Clinical Trial of Nano Anticancer Drug, PRD-101

SEONGNAM, South Korea, Feb. 6, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO:Jihoon Sohn) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PRD-101, enabling the initiation of a Phase 1 clinical trial inthe United ...

2026-02-06 15:20 4721

Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis

SHANGHAI, Feb. 6, 2026  /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China's National Medical Products...

2026-02-06 13:10 4632

Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer

HONG KONG, Feb. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the National Medic...

2026-02-06 10:26 5335

Sky Labs Signs Exclusive Distribution Agreement with Otsuka Pharmaceutical for 'CART BP pro' in Japan

- Secures distribution agreement to launch CART BP pro in the Japanese hospital and clinic market - Leveraging proven technology with adoptions in 1,700+ medical institutions and national health insurance coverage in Korea SEOUL, South Korea, Feb. 5, 2026 /PRNewswire/ -- Sky Labs Inc. (CEO Jack ...

2026-02-06 09:00 3904

World's First Serum-Free Iterative Rabies Vaccine from AIM Successfully Passes On-Site Registration Inspections and Is Imminent for Launch

HONG KONG, Feb. 6, 2026 /PRNewswire/ -- Poised to Fill the Global Market Gap, the Serum-Free Iterative Rabies Vaccine Approaches a Critical Milestone in Commercialization. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on February 5 that its wholly-owned subsidiary AIM Rong...

2026-02-06 07:30 5655

VARON Marks Valentine's Day With Health-Focused Savings That Put Care First

Love looks like care. This Valentine's Day, VARON invites families to show love in a way that helps loved ones breathe easier—at home and on the go. NEW YORK, Feb. 5, 2026 /PRNewswire/ -- VARON

2026-02-06 07:18 4292

This Valentine's Day, VARON Encourages Filipinos to Show Love Through Better Respiratory Health

MANILA, Philippines, Feb. 5, 2026 /PRNewswire/ -- Valentine's Day is traditionally associated with flowers and chocolates, but health experts encourage Filipinos to also prioritize well-being for themselves and their loved ones. Respiratory health is increasingly important as more people manage ...

2026-02-06 07:11 4370

Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026

Demonstrating Instantaneous Ablation Through High-Voltage Waveforms and Efficient Point-by-Point Pulsed Field Ablation CARDIFF-BY-THE-SEA, Calif., Feb. 6, 2026 /PRNewswire/ -- Field Medical, Inc., a clinical-stage medical technology company advancing pulsed field ablation (PFA) solutions for com...

2026-02-06 06:40 5786

Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas

MUMBAI, India, Feb. 6, 2026 /PRNewswire/ -- Piramal Critical Care, Inc. (PCC), an overseas subsidiary of Piramal Pharma Limited, and Blue-Zone Technologies Ltd. (Blue-Zone) announced an agreement to collaborate on full lifecycle technology to capture and recycle waste anaesthetic gases. By combi...

2026-02-06 01:04 6528

Sore Back After Pre-New Year Cleaning? Herbalgy's "Wellness Declutter" Method Shares 3 Tips to Sweep Away Pain for a Light, Energetic New Year

HONG KONG, Feb. 5, 2026 /PRNewswire/ -- As Lunar New Year approaches, many households dive into their annual deep cleaning, hoping to start the year in a fresh, orderly environment. However, intensive cleaning in a short period—repeated bending, squatting, kneeling, or lifting, can quickly lead t...

2026-02-05 22:38 5772

LifeZoom Introduces the Oclux Red Light Eye Mask--A Naturally Restorative, Aesthetics-Driven Solution for the Effects of Screen-Based Life

NEW YORK, Feb. 5, 2026 /PRNewswire/ -- LifeZoom, a natural-restorative brand, today launches Oclux, a red light eye mask that expands the company's red light product lineup. Positioned as a holistic solution that balances visual aesthetics, user experience, and daily rhythms, Oclux is designed to...

2026-02-05 22:12 5178

Jin Medical CEO Fireside Chat

CHANGZHOU, China, Feb. 5, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ:ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment hosted a CEO Fireside Chat onFebruary 2, 2026 where the CEO sha...

2026-02-05 21:57 6880

Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications

* NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source. * Unlike ISM8969, Insilico's brain-penetrant NLR...

2026-02-05 21:00 5746

Providence Therapeutics Announces Appointment of Leah Goodman to the Board of Directors

Leah Goodman brings a wealth of policy and regulatory experience and is a recognized leader in Australia for advancing scientific discoveries to patient impacts. CALGARY, AB and BRISBANE, Australia, Feb. 5, 2026 /PRNewswire/ -- Providence Therapeutics, a Canadian clinical-stage mRNA biotechnolog...

2026-02-05 21:00 5027

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters:Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive developm...

2026-02-05 19:44 4689

Leading Chinese Innovative Medical Device Maker Insight Lifetech Has Successfully Listed on STAR Market

SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Insight Lifetech, a portfolio company of Qiming Venture Partners and a leading Chinese innovative medical device manfaucturer, successfully listed on the Shanghai Stock Exchange's STAR Market on February 5, 2026 Beijing time. Insight Lifetech (688712.SH) iss...

2026-02-05 19:39 5431

HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026

Sustained execution and high-impact data across HanchorBio's next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC TAIPEI and SHANGHAI and SAN FRANCISCO, Feb. 4, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechno...

2026-02-05 17:09 5699

Galaxy Brain Scientific's Technology Enables Landmark Parkinson's Study Published in Nature, Redefining Disease Mechanism

BEIJING, Feb. 5, 2026 /PRNewswire/ -- A research team led by Prof. Hesheng Liu, founder and Chief Scientific Officer of Galaxy Brain Scientific Inc., has published a study inNature that pinpoints the core functional circuit underlying Parkinson's disease (PD). The findings redefine the biological...

2026-02-05 13:00 4684

Moleac is pleased to announce that NeuroAiD™II has been awarded Gold accreditation by Empowered By Evidence.

SINGAPORE, Feb. 5, 2026 /PRNewswire/ -- This recognition reflects the robust clinical evidence supporting NeuroAiD™II, as well as the uniqueness of its formulation, the rigour of its manufacturing, reproducibility, and quality control, highlighting its reliability and value in supporting neurolog...

2026-02-05 11:48 6670
1 ... 45678910 ... 855